<DOC>
	<DOC>NCT00143143</DOC>
	<brief_summary>The primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.</brief_summary>
	<brief_title>Pregabalin Open-Label Extension Trial in Patients With Partial Seizures</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies, Partial</mesh_term>
	<mesh_term>Epilepsy, Complex Partial</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Patients must have met the inclusion criteria for Study 1008157, have received doubleblind study medication, and wish to receive openlabel pregabalin Have the diagnosis of epilepsy with partial seizures and have a minimum of 4 partial seizures during the 6 weeks prior to screening Be currently taking 1 to 3 AEDs. Have a treatable cause of seizures Experienced a serious adverse event during Study 1008157 which was determined to be possibly related to study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2006</verification_date>
</DOC>